Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-channel antithrombotic therapy to prevent left ventricular thrombosis after acute anterior wall myocardial infarction
ChiCTR2100050255Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor and rivaroxaban in myocardial infarction (MI) and coronary arteriosclerosis (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Rate of left ventricular thrombosis. Started Aug 2021; status: recruiting.
02
Drugs
ticagrelorrivaroxaban
03
Conditions
myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2100050255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050255.